STERIS Corporation Initiates Expense Reduction Program to Generate $30 Million In Annualized Savings
31 Marzo 2008 - 6:00AM
PR Newswire (US)
Program Currently Being Implemented with Partial Benefits to Be
Realized in Fiscal Year 2009 MENTOR, Ohio, March 31
/PRNewswire-FirstCall/ -- STERIS Corporation (NYSE: STE) today
announced that it has initiated a program to enhance profitability
and improve efficiency by generating annualized operating expense
savings of approximately $30 million. As a result of the program,
the Company will incur a pre-tax charge of approximately $15
million during the quarter ending March 31, 2008, primarily related
to severance benefits and asset write downs. Excluding the charge,
the Company reiterated its previously announced earnings range of
$1.30 to $1.35 per diluted share for the full fiscal year 2008. The
Company noted that it anticipates realizing approximately 50% to
70% of the identified operating expense savings during its fiscal
year ending March 31, 2009 and will provide additional detail on
expected fiscal 2009 performance in its earnings announcement
scheduled for May 7, 2008. "While the focus of the Company is
centered on meeting the needs of our customers and enhancing our
legacy of product quality and innovation, it is important that we
re-shape the operating model of the Company to drive profitable
growth," said Walt Rosebrough, president and chief executive
officer of STERIS. "Decisions like this are always difficult and we
very much appreciate the contributions of those employees who have
been affected. However, it is important that we become more
disciplined with our overhead expenditure levels, which in recent
times have increased at a faster pace than revenues, and focus our
resources on ensuring that our customers are well served." Under
the program, the Company expects to reduce its compensation (salary
and benefits) expenditures by reducing management layers,
eliminating redundancies and consolidating functions where
appropriate. The remaining savings are anticipated to come
primarily from a reduction in indirect overhead expenses through
the reduced consumption of goods and services and the consolidation
of service providers. The Company noted that the program and
estimated savings largely reflects a focus on North American
operations but believes that further cost reductions will be
identified in international operations. About STERIS The mission of
STERIS Corporation is to provide a healthier today and safer
tomorrow through knowledgeable people and innovative infection
prevention, decontamination and health science technologies,
products and services. The Company's more than 5,000 dedicated
employees around the world work together to supply a broad array of
solutions by offering a combination of equipment, consumables and
services to healthcare, pharmaceutical, industrial and government
customers. The Company is listed on the New York Stock Exchange
under the symbol STE. For more information, visit
http://www.steris.com/. This news release may contain statements
concerning certain trends, expectations, forecasts, estimates, or
other forward-looking information affecting or relating to the
Company or its industry that are intended to qualify for the
protections afforded "forward-looking statements" under the Private
Securities Litigation Reform Act of 1995 and other laws and
regulations. Forward-looking statements speak only as to the date
of this report, and may be identified by the use of forward-looking
terms such as "may," "will," "expects," "believes," "anticipates,"
"plans," "estimates," "projects," "targets," "forecasts,"
"confidence," and "seeks," or the negative of such terms or other
variations on such terms or comparable terminology. Many important
factors could cause actual results to differ materially from those
in the forward-looking statements including, without limitation,
disruption of production or supplies, changes in market conditions,
political events, pending or future claims or litigation,
competitive factors, technology advances, and changes in government
regulations or the application or interpretation thereof. Other
risk factors are described in the Company's Form 10-K and other
securities filings. Many of these important factors are outside
STERIS's control. No assurances can be provided as to any level of
expense reduction or other future financial results. Unless legally
required, the Company does not undertake to update or revise any
forward-looking statements even if events make clear that any
projected results, express or implied, will not be realized. Other
potential risks and uncertainties that could cause actual results
to differ materially from those in the forward- looking statements
include, without limitation, (a) the potential for increased
pressure on pricing that leads to erosion of profit margins, (b)
the possibility that market demand will not develop for new
technologies, products or applications, or the Company's business
initiatives will take longer, cost more or produce lower benefits
than anticipated, (c) the possibility that application of or
compliance with laws, court rulings, regulations, certifications or
other requirements or standards may delay or prevent new product
introductions, affect the production and marketing of existing
products, or otherwise affect Company performance, results, or
value, (d) the potential of international unrest or effects of
fluctuations in currencies, tax assessments or rates, raw material
costs, benefit or retirement plan costs, or other regulatory
compliance costs, (e) the possibility of reduced demand, or
reductions in the rate of growth in demand, for the Company's
products and services, and (f) the possibility that anticipated
cost savings may not be achieved, or that transition, labor,
competition, timing, execution, regulatory, governmental, or other
issues or risks associated with the matters described in this
release may adversely impact Company performance, results, or
value. DATASOURCE: STERIS Corporation CONTACT: Aidan Gormley,
Senior Director, Corporate Communications and Investor Relations of
STERIS Corporation, +1-440-392-7607 Web site:
http://www.steris.com/
Copyright